307 related articles for article (PubMed ID: 19308744)
1. [Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].
Noguera O; Rodríguez JC; López JM; Ruiz M; Royo G
Rev Esp Quimioter; 2009 Mar; 22(1):30-3. PubMed ID: 19308744
[TBL] [Abstract][Full Text] [Related]
2. Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.
Daoud Z; Sokhn ES; Azar E; Masri K; Doron S
J Infect Dev Ctries; 2014 Feb; 8(2):154-9. PubMed ID: 24518624
[TBL] [Abstract][Full Text] [Related]
3. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
Puerto AS; Fernández JG; del Castillo Jde D; Pino MJ; Angulo GP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lautenbach E; Strom BL; Bilker WB; Patel JB; Edelstein PH; Fishman NO
Clin Infect Dis; 2001 Oct; 33(8):1288-94. PubMed ID: 11565067
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Biedenbach DJ; Toleman M; Walsh TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
[TBL] [Abstract][Full Text] [Related]
7. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.
Yokota S; Sato T; Okubo T; Ohkoshi Y; Okabayashi T; Kuwahara O; Tamura Y; Fujii N
Chemotherapy; 2012; 58(1):52-9. PubMed ID: 22343392
[TBL] [Abstract][Full Text] [Related]
10. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
[TBL] [Abstract][Full Text] [Related]
11. [Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in pediatric patients in China].
Wang L; Yang YH; Lu Q; Wang Y; Chen Y; Deng L; Deng QL; Zhang H; Wang CQ; Liu L; Xu XW; Shen XZ
Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1372-5. PubMed ID: 18953872
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
[TBL] [Abstract][Full Text] [Related]
13. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
Akyar I
Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models.
Cebríán L; Rodríguez JC; Escribiano I; Royo SG
APMIS; 2007 Dec; 115(12):1376-82. PubMed ID: 18184408
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp].
Ekşi F; Ozer G; Balci I
Mikrobiyol Bul; 2007 Jul; 41(3):447-52. PubMed ID: 17933257
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives.
Pokharel BM; Koirala J; Dahal RK; Mishra SK; Khadga PK; Tuladhar NR
Int J Infect Dis; 2006 Nov; 10(6):434-8. PubMed ID: 16978898
[TBL] [Abstract][Full Text] [Related]
17. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
18. Detection of drug-resistant Escherichia coli in patients with complicated cystitis: analysis of risk factors.
Shigehara K; Uchibayashi T; Maeda E; Namiki M
Int J Urol; 2009 Oct; 16(10):808-12. PubMed ID: 19659550
[TBL] [Abstract][Full Text] [Related]
19. Activities of the frog skin peptide, ascaphin-8 and its lysine-substituted analogs against clinical isolates of extended-spectrum beta-lactamase (ESBL) producing bacteria.
Eley A; Ibrahim M; Kurdi SE; Conlon JM
Peptides; 2008 Jan; 29(1):25-30. PubMed ID: 18068868
[TBL] [Abstract][Full Text] [Related]
20. Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States.
Bhusal Y; Mihu CN; Tarrand JJ; Rolston KV
Chemotherapy; 2011; 57(4):335-8. PubMed ID: 21912115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
